Popular on EntSun
- Electives Appoints DraftKings' CPO Linda Aiello to Board Amid Record Quarter - 195
- Mission 3A Establishes Healthcare Advisory Board with Addition of Industry Leaders Patrick Fisher, Kevin Cordell, and Dr. Greg Berlet - 183
- Retirement Income Specialist Daniel Rondberg Joins Tom Hegna on the Exciting New Season of "Financial Freedom with Tom Hegna" - 146
- OpsVeda Announces Launch of TariffSight, the World's First Comprehensive Platform to Address Tariff-Driven Challenges - 122
- Tobu Railway Announces a Price Revision on the "NIKKO PASS All Area" and "NIKKO PASS World Heritage Area," from April 20, 2025 - 116
- Meditech International Inc. and Los Angeles Rams Continue Strategic Partnership to Enhance Athlete Performance and Recovery - 115
- Deevid.ai Unveils AI Kissing and AI Dancing Templates to Power Viral TikTok Content Creation - 114
- Multi-Award Winning B.Slade to Debut in Las Vegas at Iconic Westgate Resort & Casino; The B.Slade Experience (BSX) — May 3, 2025 - 110
- Family Estrangement on the Rise: Therapist Offers Support, Perspective, and Community for Those Affected - 110
- Is Billboard Advertising Still Effective in 2025? - 102
Similar on EntSun
- PBK Miner completes $80 million Series B financing to support AI cloud mining and increase user investment return by 25%
- Asset-Backed Green Crypto: Fueling the Trillion-Dollar Revolution
- NBA Champion Lamar Odom Launches Anti-Addiction Meme Coin, Ushering in a Disruptive Innovation in Web3
- Cybersecurity is Protecting Your Personal Information and Your Portfolio
- The Paris Court of International Arbitration Elects Dr. John J. Maalouf as its New President
- $56.7 Million Announced in Q1 2025 with Revenue Growth and Progress Toward NASDAQ Uplisting for AI Marketing Company: IQSTEL, Inc. Stock Symbol: IQSTD
- SAVVY MINING raised $500 million and launched BTC.XRP.DOGE cloud mining, increasing investors' returns by 30%
- Ditch Micromanagement: New Leadership Book for Results-Driven, Accountability-Based Teams
- Jay Tapp was named Managing Director in British Columbia
- 20 Patents Issued Worldwide, Cementing Company Leadership. First Ever Cable-Free 12-Lead ECG: HeartBeam, Inc. (Stock Symbol: BEAT)
INVESTOR DEADLINE: Investors in Enochian Biosciences Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – ENOB
EntSun News/10949389
SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Enochian Biosciences Inc. (NASDAQ: ENOB) securities between January 17, 2018 and June 27, 2022, inclusive (the "Class Period") have until September 26, 2022 to seek appointment as lead plaintiff in the Enochian Biosciences class action lawsuit. The Enochian Biosciences class action lawsuit – captioned Chow v. Enochian Biosciences Inc., No. 22-cv-05147 (C.D. Cal.) – charges Enochian Biosciences Inc. as well as certain of its directors and officers with violations of the Securities Exchange Act of 1934. A subsequently filed complaint, Manici v. Enochian Biosciences Inc., No. 22-cv-05237, is also pending in the Central District of California.
If you suffered substantial losses and wish to serve as lead plaintiff, please provide your information here:
https://www.rgrdlaw.com/cases-enochian-biosciences-inc-class-action-lawsuit-enob.html
You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at jsanchez@rgrdlaw.com.
CASE ALLEGATIONS: Enochian Biosciences is a pre-clinical stage biotechnology company that purportedly researches and develops pharmaceutical and biological products for the human treatment of HIV, HBV, influenza and coronavirus infections, and cancer. Enochian Biosciences and its top management have credited Serhat Gumrukcu ("Gumrukcu"), Enochian Biosciences' co-founder, as the "inventor" of the technology and science behind Enochian Biosciences' product pipeline. Enochian Biosciences has multiple consulting and licensing agreements with G-Tech Bio, LLC, a California limited liability company ("G-Tech"), and G Health Research Foundation, a not-for-profit entity organized under the laws of California doing business as Seraph Research Institute ("SRI"), both of which are controlled by Gumrukcu.
More on EntSun News
The Enochian Biosciences class action lawsuit alleges that, throughout the Class Period, defendants made false and misleading statements and failed to disclose that: (i) Gumrukcu was not a licensed doctor and had no verifiable degrees beyond high school; (ii) accordingly, the scientific and technological underpinnings of Enochian Biosciences' product pipeline, purportedly invented by Gumrukcu, were dubious at best; (iii) accordingly, Enochian Biosciences had significantly overstated the commercial prospects for Enochian Biosciences' product pipeline; (iv) Enochian Biosciences' senior leadership knew Gumrukcu had a criminal history that included fraud; (v) accordingly, Enochian Biosciences' reliance on Gumrukcu, and its consulting and licensing agreements with G-Tech and SRI, subjected Enochian Biosciences to a heightened risk of reputational and financial harm, as well as threatened the integrity of Enochian Biosciences' scientific findings; and (vi) as a result, Enochian Biosciences' public statements were materially false and misleading at all relevant times.
On May 25, 2022, the U.S. Department of Justice announced that Gumrukcu had been arrested and charged in a murder-for-hire conspiracy. On this news, Enochian Biosciences' stock price fell by just under 37%, damaging investors.
Then, on June 1, 2022, Hindenburg Research published a report on Enochian Biosciences entitled "Miracle Cures and Murder For Hire: How A Spoon-Bending Turkish Magician Built A $600 Million Nasdaq-Listed Scam Based On A Lifetime Of Lies," which noted that the individual in whose murder Gumrukcu was implicated, Gregory Davis, "was murdered . . . just 19 days before Gumrukcu was scheduled to appear in court to defend himself against felony fraud allegations related to a 2016 deal with Davis" and that "[f]ederal prosecutors argued that the prospective merger deal that eventually resulted in Enochian [Biosciences] going public served as a key motive for the murder." The Hindenburg Research report also stated that "[u]nbeknownst to investors (but known to Enochian [Biosciences'] senior leadership) Gumrukcu's latest arrest for a murder conspiracy is simply the most recent in a string of alleged crimes by Gumrukcu," who "was arrested based on accusations of falsely posing as a doctor" in his native Turkey in 2012 and "[i]n February 2017, Gumrukcu was arrested by authorities after the State of California accused him of a slew of white-collar crimes, including fraud, identity theft, and check kiting – a total of 14 felonies." On this news, Enochian Biosciences' stock price fell by more than 28%.
More on EntSun News
Finally, on June 27, 2022, The Wall Street Journal published an article about Gumrukcu's participation in the murder-for-hire conspiracy, claiming that Gumrukcu owed Davis over $900,000 after Gumrukcu coaxed Davis into entering into a fraudulent oil deal with him. The article further alleged that FBI agents were suspicious that Gumrukcu "had fabricated his resume and held neither a medical degree nor a doctoral degree." On this news, Enochian Biosciences' stock price fell an additional 21.9%, further damaging investors.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Enochian Biosciences securities during the Class Period to seek appointment as lead plaintiff. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Enochian Biosciences class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Enochian Biosciences class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Enochian Biosciences class action lawsuit.
ABOUT ROBBINS GELLER: Robbins Geller is one of the world's leading complex class action firms representing plaintiffs in securities fraud cases. The Firm is ranked #1 on the 2021 ISS Securities Class Action Services Top 50 Report for recovering nearly $2 billion for investors last year alone – more than triple the amount recovered by any other plaintiffs' firm. With 200 lawyers in 9 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:
https://www.rgrdlaw.com/services-litigation-securities-fraud.html
Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Contacts
Robbins Geller Rudman & Dowd LLP
655 W. Broadway, Suite 1900, San Diego, CA 92101
J.C. Sanchez, 800-449-4900
jsanchez@rgrdlaw.com
If you suffered substantial losses and wish to serve as lead plaintiff, please provide your information here:
https://www.rgrdlaw.com/cases-enochian-biosciences-inc-class-action-lawsuit-enob.html
You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at jsanchez@rgrdlaw.com.
CASE ALLEGATIONS: Enochian Biosciences is a pre-clinical stage biotechnology company that purportedly researches and develops pharmaceutical and biological products for the human treatment of HIV, HBV, influenza and coronavirus infections, and cancer. Enochian Biosciences and its top management have credited Serhat Gumrukcu ("Gumrukcu"), Enochian Biosciences' co-founder, as the "inventor" of the technology and science behind Enochian Biosciences' product pipeline. Enochian Biosciences has multiple consulting and licensing agreements with G-Tech Bio, LLC, a California limited liability company ("G-Tech"), and G Health Research Foundation, a not-for-profit entity organized under the laws of California doing business as Seraph Research Institute ("SRI"), both of which are controlled by Gumrukcu.
More on EntSun News
- Vortex Brands Begins Gold Purchases Under New Joint Venture with Dubai-Based Partner
- Sell Your Rolex, Audemars Piguet (AP), and Patek Philippe Watches at David and Sons Timepieces
- Miss United Crown of America Launches as a National Platform for Purpose-Driven Titleholders
- Big Red NOLA Publishing Boosts "Voices of Tomorrow"
- NBA Champion Lamar Odom Launches Anti-Addiction Meme Coin, Ushering in a Disruptive Innovation in Web3
The Enochian Biosciences class action lawsuit alleges that, throughout the Class Period, defendants made false and misleading statements and failed to disclose that: (i) Gumrukcu was not a licensed doctor and had no verifiable degrees beyond high school; (ii) accordingly, the scientific and technological underpinnings of Enochian Biosciences' product pipeline, purportedly invented by Gumrukcu, were dubious at best; (iii) accordingly, Enochian Biosciences had significantly overstated the commercial prospects for Enochian Biosciences' product pipeline; (iv) Enochian Biosciences' senior leadership knew Gumrukcu had a criminal history that included fraud; (v) accordingly, Enochian Biosciences' reliance on Gumrukcu, and its consulting and licensing agreements with G-Tech and SRI, subjected Enochian Biosciences to a heightened risk of reputational and financial harm, as well as threatened the integrity of Enochian Biosciences' scientific findings; and (vi) as a result, Enochian Biosciences' public statements were materially false and misleading at all relevant times.
On May 25, 2022, the U.S. Department of Justice announced that Gumrukcu had been arrested and charged in a murder-for-hire conspiracy. On this news, Enochian Biosciences' stock price fell by just under 37%, damaging investors.
Then, on June 1, 2022, Hindenburg Research published a report on Enochian Biosciences entitled "Miracle Cures and Murder For Hire: How A Spoon-Bending Turkish Magician Built A $600 Million Nasdaq-Listed Scam Based On A Lifetime Of Lies," which noted that the individual in whose murder Gumrukcu was implicated, Gregory Davis, "was murdered . . . just 19 days before Gumrukcu was scheduled to appear in court to defend himself against felony fraud allegations related to a 2016 deal with Davis" and that "[f]ederal prosecutors argued that the prospective merger deal that eventually resulted in Enochian [Biosciences] going public served as a key motive for the murder." The Hindenburg Research report also stated that "[u]nbeknownst to investors (but known to Enochian [Biosciences'] senior leadership) Gumrukcu's latest arrest for a murder conspiracy is simply the most recent in a string of alleged crimes by Gumrukcu," who "was arrested based on accusations of falsely posing as a doctor" in his native Turkey in 2012 and "[i]n February 2017, Gumrukcu was arrested by authorities after the State of California accused him of a slew of white-collar crimes, including fraud, identity theft, and check kiting – a total of 14 felonies." On this news, Enochian Biosciences' stock price fell by more than 28%.
More on EntSun News
- Aureli Construction Sets the Standard for Seamless Home Additions in Greater Boston
- ScreenPoints Puts Film Investors in the Credits—and in the Money With New FinTech Platform
- Pathways to Adulthood Conference May 17 at Melville Marriott Honoring NYS Assembly Member Jodi Giglio, Suffolk County Legislator Nick Caracappa
- KBA Sports and 6x Entertainment Join Forces to Become Global Sports Partners
- Adster Techologies awarded US Patent for breakthrough innovation in reducing latency in Ad Serving
Finally, on June 27, 2022, The Wall Street Journal published an article about Gumrukcu's participation in the murder-for-hire conspiracy, claiming that Gumrukcu owed Davis over $900,000 after Gumrukcu coaxed Davis into entering into a fraudulent oil deal with him. The article further alleged that FBI agents were suspicious that Gumrukcu "had fabricated his resume and held neither a medical degree nor a doctoral degree." On this news, Enochian Biosciences' stock price fell an additional 21.9%, further damaging investors.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Enochian Biosciences securities during the Class Period to seek appointment as lead plaintiff. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Enochian Biosciences class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Enochian Biosciences class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Enochian Biosciences class action lawsuit.
ABOUT ROBBINS GELLER: Robbins Geller is one of the world's leading complex class action firms representing plaintiffs in securities fraud cases. The Firm is ranked #1 on the 2021 ISS Securities Class Action Services Top 50 Report for recovering nearly $2 billion for investors last year alone – more than triple the amount recovered by any other plaintiffs' firm. With 200 lawyers in 9 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:
https://www.rgrdlaw.com/services-litigation-securities-fraud.html
Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Contacts
Robbins Geller Rudman & Dowd LLP
655 W. Broadway, Suite 1900, San Diego, CA 92101
J.C. Sanchez, 800-449-4900
jsanchez@rgrdlaw.com
Filed Under: Business
0 Comments
Latest on EntSun News
- SLP Couture Presents "Murderous Love"
- ImagineX, in Collaboration with Qualys, Launches New mROC Services to Transform Enterprise Cyber Risk Management
- Ditch Micromanagement: New Leadership Book for Results-Driven, Accountability-Based Teams
- Jay Tapp was named Managing Director in British Columbia
- World Ballet Company's Cinderella Comes to the Weinberg Center This Fall
- Hubei Heavy Equipment Makes a Striking Appearance at CIMT and Competes with International Brands
- 20 Patents Issued Worldwide, Cementing Company Leadership. First Ever Cable-Free 12-Lead ECG: HeartBeam, Inc. (Stock Symbol: BEAT)
- NASDAQ Uplisting for Higher Market Exposure and Wide Corporate Benefits to AI Boosted Marketing Company On Track Towards $1 Billion Revenue by 2027
- Congressional Men's Health Caucus Shows Bipartisan Consensus and Focus on Prevention, Mental Health, and Closing the Lifespan Gap
- DuoKey, Axiomtek and Blue Edge Network Partner to Enhance Smart Cities with Privacy-Preserving Urban Safeguarding and Fleet Management
- Austin Keen Joins WakeFX RopePal as Official Brand Ambassador
- Bonelli Systems Expands Managed IT Services Nationwide, Leveraging Microsoft Azure Expertise
- $4.3 Million Patent Application Waiver Fee Granted by FDA on New Drug Application Fee for Treatment Addressing Suicidal Depression & PTSD: NRX Pharma
- Whistleblower Claims Dental Patient Deaths Likely Due to Book Ban
- xREnergy up as much as +3,094,634% on first day listed on the XRP Ledger. Ticker : $XRE
- Psychiatry's Legacy of Racism and Coercion Highlighted in Restraint Deaths
- New Book 'Cybersecurity Leadership' Guides SME Leaders to Make Smart, Strategic Security Decisions
- "Stop scrolling and start watching" - Beloved film recommendation site Criticker gets a major makeover
- Green Energy Solar Expands with New Offices in Port St. Lucie, West Palm Beach, and Orlando
- Events by Dubsdread Expands Services to The Venue at Lake Lily